With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Plans to double its manufacturing footprint to bolster the growth
Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum
The award was presented to Biocon Foundation as a mark of recognition of various projects undertaken during the year for reducing the environmental impact on cities
Subscribe To Our Newsletter & Stay Updated
